Prostate Cancer News
The daily prostate cancer news is a unique cancer news service that evaluates all aspects of prostate cancer research and reports on the developments that are most important to cancer patients and health care providers. The daily cancer news provides information about emerging options for prostate cancer prevention, early detection and prostate cancer treatment, as well as advances in supportive care and personalized medicine. Supportive care improves quality of life by making prostate cancer treatment more tolerable, and personalized medicine offers the potential for improved treatment outcomes by using specific characteristics of the patient or the cancer to guide cancer treatment decisions. In addition, interested individuals can search the Cancer Consultants Prostate Cancer News Archives to find the results of the cancer studies that led to the care they have been offered.
Prostate Cancer News
Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)
People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying... Continue Reading
A new genetic test—the Oncotype DX® Prostate Cancer Test—measures the aggressiveness of prostate cancer and may help scores of men choose between immediate treatment or active surveillance. The test... Continue Reading
Immediate radiation therapy after radical prostatectomy resulted in a 50 percent increase in long-term biochemical progression-free survival (bNED) in men with locally advanced prostate cancer, according... Continue Reading
Men with localized prostate cancer experience declines in sexual, urinary, and bowel function over time, regardless of whether they choose surgery or radiation therapy, according to the results of a study... Continue Reading
Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National... Continue Reading
Proton therapy does not reduce toxicity compared with intensity-modulated radiation therapy (IMRT) in men with prostate cancer, according to the results of a study published in the Journal of the National... Continue Reading
Screening for prostate cancer carries some risks and can affect quality of life. Considering these risks is important when making the decision about whether to be screened. The results of a study that... Continue Reading
The U.S. Food and Drug Administration (FDA) has expanded the approved use of Zytiga® (abiraterone) to treat men with metastatic, hormone-refractory prostate cancer prior to receiving chemotherapy. Prostate... Continue Reading
Managing Side Effects and Maximizing Health During & After Prostate Cancer Treatment: Web Chat with Neal D. Shore, MD Neal D. Shore, MD, FACS, is the medical director of the Carolina Urologic Research... Continue Reading
Viagra® (sildenafil citrate) administered before, during, and after radiation therapy improved overall sexual function in prostate cancer patients, according to the results of a study presented at the... Continue Reading
Latest Prostate Cancer News By Stage
Screening and Prevention
Prostate Cancer Screening Can Take a Toll on Quality of Life (December 19, 2012)
Screening for prostate cancer carries some risks and can affect quality of life. Considering these risks is important when making the decision about whether to be screened. The results of a study that assessed both the potential benefits of screening... Continue Reading
PSA Testing May Be Appropriate for Some Men (July 25, 2012)The American Society of Clinical Oncology (ASCO) has released a Provisional Clinical Opinion (PCO) suggesting that that men with a longer life expectancy—those with at least 10 more years to live—discuss with their physician the potential risks and... Continue Reading
Side Effects of Prostate Cancer Treatment Persist Long-Term (July 5, 2012)Men who are treated for prostate cancer may continue to suffer from side effects 10 years after treatment, according to the results of a study published in the Journal of Clinical Oncology. Each year in the United States, more than 192,000 men are diagnosed... Continue Reading
Number of Cancer Survivors Will Grow to 18 Million by 2022 (June 25, 2012)There will be nearly 18 million cancer survivors in the United States by 2022, according to a report by the American Cancer Society and the National Cancer Institute: Cancer Treatment & Survivorship Facts & Figures[1] and an accompanying journal... Continue Reading
Prostate Screening Not Recommended for Older Men (June 1, 2012)The U.S. Preventive Services Task Force (USPSTF) recently drafted a grade D recommendation against prostate-specific antigen (PSA) screening for prostate cancer; however, it is unclear how this will affect screening practices since their previous recommendation... Continue Reading
More Screening and PreventionEarly Stage I-II (A-B)
Genomic Test May Help Guide Prostate Cancer Treatment (May 13, 2013)
A new genetic test—the Oncotype DX® Prostate Cancer Test—measures the aggressiveness of prostate cancer and may help scores of men choose between immediate treatment or active surveillance. The test was shown to strongly predict aggressiveness of... Continue Reading
Surgery and Radiation for Prostate Cancer Produce Similar Functional Outcomes (February 27, 2013)Men with localized prostate cancer experience declines in sexual, urinary, and bowel function over time, regardless of whether they choose surgery or radiation therapy, according to the results of a study published in the New England Journal of Medicine. Each... Continue Reading
No Difference in Toxicity Between Proton Therapy and IMRT for Prostate Cancer (January 28, 2013)Proton therapy does not reduce toxicity compared with intensity-modulated radiation therapy (IMRT) in men with prostate cancer, according to the results of a study published in the Journal of the National Cancer Institute. Prostate cancer is the most... Continue Reading
Web Chat with Dr. Shore on Managing Side Effects and Maximizing Health During & After Prostate Cancer Treatment (November 26, 2012)Managing Side Effects and Maximizing Health During & After Prostate Cancer Treatment: Web Chat with Neal D. Shore, MD Neal D. Shore, MD, FACS, is the medical director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and the... Continue Reading
Viagra Improves Sexual Function after Radiation for Prostate Cancer (November 15, 2012)Viagra® (sildenafil citrate) administered before, during, and after radiation therapy improved overall sexual function in prostate cancer patients, according to the results of a study presented at the 54th annual meeting of the American Society for Radiation... Continue Reading
More Early Stage I-II (A-B)Locally Advanced Stage III (C)
Genomic Test May Help Guide Prostate Cancer Treatment (May 13, 2013)
A new genetic test—the Oncotype DX® Prostate Cancer Test—measures the aggressiveness of prostate cancer and may help scores of men choose between immediate treatment or active surveillance. The test was shown to strongly predict aggressiveness of... Continue Reading
Early Radiation Improves Prostate Cancer Survival (March 7, 2013)Immediate radiation therapy after radical prostatectomy resulted in a 50 percent increase in long-term biochemical progression-free survival (bNED) in men with locally advanced prostate cancer, according to the results of a study presented at the Genitourinary... Continue Reading
No Difference in Toxicity Between Proton Therapy and IMRT for Prostate Cancer (January 28, 2013)Proton therapy does not reduce toxicity compared with intensity-modulated radiation therapy (IMRT) in men with prostate cancer, according to the results of a study published in the Journal of the National Cancer Institute. Prostate cancer is the most... Continue Reading
Web Chat with Dr. Shore on Managing Side Effects and Maximizing Health During & After Prostate Cancer Treatment (November 26, 2012)Managing Side Effects and Maximizing Health During & After Prostate Cancer Treatment: Web Chat with Neal D. Shore, MD Neal D. Shore, MD, FACS, is the medical director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and the... Continue Reading
Viagra Improves Sexual Function after Radiation for Prostate Cancer (November 15, 2012)Viagra® (sildenafil citrate) administered before, during, and after radiation therapy improved overall sexual function in prostate cancer patients, according to the results of a study presented at the 54th annual meeting of the American Society for Radiation... Continue Reading
More Locally Advanced Stage III (C)Metastatic Stage IV (D)
Genomic Test May Help Guide Prostate Cancer Treatment (May 13, 2013)
A new genetic test—the Oncotype DX® Prostate Cancer Test—measures the aggressiveness of prostate cancer and may help scores of men choose between immediate treatment or active surveillance. The test was shown to strongly predict aggressiveness of... Continue Reading
No Difference in Toxicity Between Proton Therapy and IMRT for Prostate Cancer (January 28, 2013)Proton therapy does not reduce toxicity compared with intensity-modulated radiation therapy (IMRT) in men with prostate cancer, according to the results of a study published in the Journal of the National Cancer Institute. Prostate cancer is the most... Continue Reading
Zytiga Approval Expanded (December 17, 2012)The U.S. Food and Drug Administration (FDA) has expanded the approved use of Zytiga® (abiraterone) to treat men with metastatic, hormone-refractory prostate cancer prior to receiving chemotherapy. Prostate cancer is a hormonally sensitive disease that... Continue Reading
Web Chat with Dr. Shore on Managing Side Effects and Maximizing Health During & After Prostate Cancer Treatment (November 26, 2012)Managing Side Effects and Maximizing Health During & After Prostate Cancer Treatment: Web Chat with Neal D. Shore, MD Neal D. Shore, MD, FACS, is the medical director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and the... Continue Reading
Intermittent and Continuous Hormone Therapy are Equally Effective in Prostate Cancer Treatment (September 18, 2012)Hormone therapy given intermittently (with breaks) has proven to be as effective as hormone therapy given continuously in asymptomatic men with rising PSA levels after prostate cancer treatment, according to the results of a study published in the New... Continue Reading
More Metastatic Stage IV (D)Refactory/Recurrent
Genomic Test May Help Guide Prostate Cancer Treatment (May 13, 2013)
A new genetic test—the Oncotype DX® Prostate Cancer Test—measures the aggressiveness of prostate cancer and may help scores of men choose between immediate treatment or active surveillance. The test was shown to strongly predict aggressiveness of... Continue Reading
No Difference in Toxicity Between Proton Therapy and IMRT for Prostate Cancer (January 28, 2013)Proton therapy does not reduce toxicity compared with intensity-modulated radiation therapy (IMRT) in men with prostate cancer, according to the results of a study published in the Journal of the National Cancer Institute. Prostate cancer is the most... Continue Reading
Web Chat with Dr. Shore on Managing Side Effects and Maximizing Health During & After Prostate Cancer Treatment (November 26, 2012)Managing Side Effects and Maximizing Health During & After Prostate Cancer Treatment: Web Chat with Neal D. Shore, MD Neal D. Shore, MD, FACS, is the medical director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and the... Continue Reading
Intermittent and Continuous Hormone Therapy are Equally Effective in Prostate Cancer Treatment (September 18, 2012)Hormone therapy given intermittently (with breaks) has proven to be as effective as hormone therapy given continuously in asymptomatic men with rising PSA levels after prostate cancer treatment, according to the results of a study published in the New... Continue Reading
Xtandi Approved for Metastatic Hormone-Refractory Prostate Cancer (September 13, 2012)The U.S. Food and Drug Administration (FDA) has approved Xtandi® (enzalutamide) for the treatment of patients with metastatic, hormone-refractory prostate cancer who have previously received docetaxel. The prostate is a male sex gland responsible for... Continue Reading
<More Refactory/Recurrent
